摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-[[4-(3-methoxypropoxy)-3-methylpyridine-2-yl]-methylsulfinyl]-1H-benzimidazole sodium salt; acetone complex

中文名称
——
中文别名
——
英文名称
2-[[4-(3-methoxypropoxy)-3-methylpyridine-2-yl]-methylsulfinyl]-1H-benzimidazole sodium salt; acetone complex
英文别名
Sodium;2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]benzimidazol-1-ide;propan-2-one;sodium;2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]benzimidazol-1-ide;propan-2-one
2-[[4-(3-methoxypropoxy)-3-methylpyridine-2-yl]-methylsulfinyl]-1H-benzimidazole sodium salt; acetone complex化学式
CAS
——
化学式
C3H6O*C18H20N3O3S*Na
mdl
——
分子量
439.511
InChiKey
DCEWBYDAZGPLIR-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.22
  • 重原子数:
    30
  • 可旋转键数:
    8
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.38
  • 拓扑面积:
    98.6
  • 氢给体数:
    0
  • 氢受体数:
    8

反应信息

点击查看最新优质反应信息

文献信息

  • Novel Processes for the Production of Amorphous Rabeprazole Sodium
    申请人:Civit Elisabeth Schuler
    公开号:US20080234486A1
    公开(公告)日:2008-09-25
    The invention is directed to overcome the problems associated with the formation of rabeprazole sodium, i.e. formation of (2-([4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methyl}sulfonyl)-1H-benzimidazole side product which is achieved by a process for the preparation of amorphous rabeprazole salt, e.g. sodium, comprising the steps of: i) contacting rabeprazole salt complex, e.g. sodium acetone complex with a first solvent system; ii) filtering the solid from the solvent system used in step i) or distilling, totally or partially, the solvent system used in step i) under reduced or atmospheric pressure, to thereby obtain a residue; iii) contacting the solid or the residue of step ii) with a second solvent system; v) filtering the solid from the solvent system used in step iii) or distilling, totally or partially, the solvent system used in step iii) under reduced or atmospheric pressure to thereby obtain a solid; v) optionally repeating steps iii) and iv) one or more times; vi) optionally filtering to obtain a wet solid; and vii) drying the wet solid.
    该发明旨在克服与拉贝拉唑钠的形成相关的问题,即通过制备非晶态拉贝拉唑盐(例如钠盐)的过程中形成(2-([4-(3-甲氧基丙氧基)-3-甲基吡啶-2-基]甲基}磺酰基)-1H-苯并咪唑)副产物的形成。该过程包括以下步骤:i)将拉贝拉唑盐复合物(例如钠丙酮复合物)与第一溶剂体系接触;ii)从步骤i)中使用的溶剂体系中过滤固体或在减压或常压下蒸馏该溶剂体系的全部或部分,以获得残留物;iii)将步骤ii)的固体或残留物与第二溶剂体系接触;v)从步骤iii)中使用的溶剂体系中过滤固体或在减压或常压下蒸馏该溶剂体系的全部或部分,以获得固体;v)可选地重复步骤iii)和iv)一次或多次;vi)可选地过滤以获得湿固体;和vii)干燥湿固体。
  • PROCESS FOR THE PREPARATION OF PURE RABEPRAZOLE
    申请人:Tyagi Om Dutt
    公开号:US20100190989A1
    公开(公告)日:2010-07-29
    The present invention relates to a process for the preparation of pure Rabeprazole sulfoxide using the solvent mixture for the extraction steps and this invention further relates to the process for the preparation of amorphous Rabeprazole sodium using pure rabeprazole base in presence of aqueous NaOH and water miscible solvent and adding an anti-solvent.
    本发明涉及一种使用溶剂混合物进行提取步骤制备纯拉贝拉唑亚砜的方法,进一步涉及一种使用纯拉贝拉唑碱在水合NaOH和水亲和性溶剂的存在下添加抗溶剂制备非晶态拉贝拉唑钠的方法。
  • IMPROVED PROCESS FOR AMOPHOUS RABEPRAZOLE SODIUM
    申请人:Parthasaradhi Reddy Bandi
    公开号:US20100204478A1
    公开(公告)日:2010-08-12
    The present invention provides an improved and efficient process for the preparation of highly pure amorphous rabeprazole sodium. Thus, for example, rabeprazole is dissolved in an alcoholic sodium hydroxide solution followed by carbon treatment, the resulting filtrate is distilled under vacuum at 50-52° C. followed by co-distillation with cyclohexane and the resulting residue is dissolved in anisole; the solution is added to cyclohexane under agitation and then the precipitated solid collected by filtration or centrifugation.
    本发明提供了一种改进和高效的过程,用于制备高纯度无定形酸碱盐。例如,将酸碱盐溶解在酒精性氢氧化钠溶液中,然后进行碳处理,所得的滤液在50-52°C下在真空下蒸馏,随后与环己烷共蒸馏,所得的残渣在苯甲醚中溶解;将溶液加入搅拌的环己烷中,然后通过过滤或离心收集沉淀的固体。
  • NOVEL PROCESSES FOR THE PRODUCTION OF AMORPHOUS RABEPRAZOLE SODIUM
    申请人:Medichem, S.A.
    公开号:EP1919902A2
    公开(公告)日:2008-05-14
  • IMPROVED PROCESS FOR AMORPHOUS RABEPRAZOLE SODIUM
    申请人:Hetero Drugs Limited
    公开号:EP2162449A2
    公开(公告)日:2010-03-17
查看更多